Standardized Ashwagandha Root Extract (KSM-66) Reduces Serum Cortisol and Subjective Stress in Healthy Adults

Ashwagandha has been valued for thousands of years in Ayurvedic medicine, but modern clinical practice requires rigorous, double-blind human trials to establish efficacy. While historically described as a strengthening and calming tonic, proving that it physically lowers the body's primary stress hormone - cortisol - is critical for its acceptance in scientific biohacking.

To address this, researchers designed a high-quality clinical trial to measure both subjective stress indices and actual blood chemistry changes following standardized Ashwagandha supplementation.

This research explainer provides a detailed breakdown of the trial design, participant selection, clinical measurements, outcomes, and molecular mechanisms of this study.

---

1. Study Design & Participant Criteria

The study was designed as a randomized, double-blind, placebo-controlled clinical trial conducted over a 60-day (8-week) period.

Participant Profiles

The trial enrolled sixty-four healthy adult volunteers (aged 18 to 45) who met the following criteria:

• Reporting chronic, elevated daily mental stress (determined via baseline psychological scales)
• Having normal liver, kidney, and thyroid function panels
• No history of psychiatric disorders or prescription psychoactive drug use
• No use of adaptogens or performance supplements within 3 months prior to enrollment

Selecting subjects with a high baseline of subjective stress was crucial. In healthy, non-stressed individuals, cortisol operates within a normal circadian range; measuring an adaptogen's homeostatic blunting effect is best demonstrated when the HPA axis is already chronically hyperactive.

The Intervention

Participants were randomly split into two groups:

1. The Active Group (32 subjects): Received 300 mg of standardized Ashwagandha root extract (patented KSM-66 extract, standardized to contain 5% active withanolides) twice daily with meals (600 mg total daily).
2. The Control Group (32 subjects): Received an identical placebo capsule containing starch.

---

2. Measurement Methodology

To ensure objective results, the researchers combined clinical blood assays with validated psychological rating instruments:

Serum Cortisol Measurement

Blood samples were drawn in the morning (between 8:00 AM and 9:00 AM) at Day 0, Day 30, and Day 60. Morning blood draws are the standard for cortisol testing, as this is when the cortisol awakening response (CAR) peaks. Checking cortisol levels at the same time ensured circadian differences did not skew the data.

Subjective Stress Scales

Subjective stress and anxiety symptoms were measured using three validated questionnaires:

• Perceived Stress Scale (PSS): Assesses the degree to which situations in life are appraised as stressful.
• General Health Questionnaire (GHQ-28): Evaluates somatic symptoms, anxiety, social dysfunction, and severe depression.
• Hamilton Anxiety Rating Scale (HAM-A): Clinician-rated scale evaluating somatic and psychic anxiety parameters.

---

3. Primary Outcomes & Findings

By Day 60, the active Ashwagandha group demonstrated statistically significant improvements across all blood biochemistry and psychological parameters compared to the placebo group.

          Serum Cortisol Reduction (Day 60)
┌──────────────────────────────────────────────┐
│Active Group: 27.9% Drop (significant blunting)│
├──────────────────────────────────────────────┤
│Placebo Group: 8.0% Drop (insignificant drift)│
└──────────────────────────────────────────────┘

Key Statistical Results

Cortisol Reduction:

• The group receiving KSM-66 Ashwagandha showed a 27.9% reduction in serum cortisol levels from baseline (dropping from an average of 15.7 ug/dL to 11.3 ug/dL).
• The placebo group showed a non-significant 8.0% reduction.

Anxiety and Stress Score Improvements:

• Scores on the Perceived Stress Scale (PSS) declined by 44.0% in the active group, compared to only 5.5% in the placebo group.
• Hamilton Anxiety (HAM-A) scores dropped by 56.5% in the active group, showing a major clinical reduction in somatic symptoms (tension, cardiovascular palpitations, trembling) and psychic anxiety (worry, fear of the future).

---

4. Understanding the Molecular Mechanism

The significant reduction in serum cortisol observed in this trial is explained by the pharmacological actions of ashwagandha's active compounds:

Pituitary-Adrenal Axis Blunting

As explained in the ashwagandha profile, the active withanolides (steroidal lactones) in ashwagandha root are structurally similar to animal hormones:

• They cross the blood-brain barrier and bind to glucocorticoid receptors in the hypothalamus and pituitary.
• This restores the sensitivity of the negative feedback loop, causing the hypothalamus to release less CRH (corticotropin-releasing hormone).
• This lowers pituitary ACTH secretion, resulting in the observed 27.9% drop in adrenal cortisol release.

GABA-A Receptor Support

Ashwagandha compounds facilitate binding at the GABA-A receptor sites. GABA is the primary inhibitory neurotransmitter that quiets the central nervous system. By supporting GABAergic pathway tone, the extract prevents the sympathetic nervous system from firing continuously, reducing next-day morning cortisol requirements.

---

5. Safety, Tolerability, and Side Effects

• Liver and Kidney Stability: All blood markers for hepatic safety (ALT, AST) and renal safety (creatinine, BUN) remained within healthy reference ranges.
• No Serious Adverse Events: No participants withdrew from the study due to supplement side effects. Minor, transient events (such as mild drowsiness in 2 participants) resolved without stopping supplementation.
• Thyroid Interplay: While not a primary outcome of this trial, researchers noted that ashwagandha can mildly elevate thyroid hormone levels (T3/T4). This is beneficial for individuals with subclinical hypothyroidism but requires caution for those with hyperthyroidism.

---

6. Trial Limitations and Future Research Needs

• Fixed Dosing: The study evaluated a single dose of 600 mg daily. Future trials comparing 300 mg, 600 mg, and 1,000 mg daily would help establish the optimal dose-response curve for stress.
• Short-Term Scope: The trial tracked participants for 60 days. Long-term studies (spanning 6 to 12 months) are needed to confirm the safety and efficacy of continuous adaptogen use and whether receptor adaptation occurs.
• Free vs. Total Cortisol: The study measured serum total cortisol. Because over 90% of circulating cortisol is bound to proteins (transcortin, albumin) and inactive, future studies should measure salivary free cortisol (which represents the active, unbound fraction).

This guide is for educational purposes only. Readers should consult qualified healthcare professionals before starting, altering, or combining any supplement routine.